Elicera Therapeutics Financials
| ELIC Stock | 2.43 0.04 1.67% |
Elicera |
Understanding current and past Elicera Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Elicera Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Elicera Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Elicera Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Elicera Therapeutics AB. Check Elicera Therapeutics' Beneish M Score to see the likelihood of Elicera Therapeutics' management manipulating its earnings.
| Instrument | Sweden Stock View All |
| Exchange | Stockholm Exchange |
| ISIN | SE0015382080 |
| Business Address | World Trade Center |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.elicera.com |
| Phone | 46 7 03 31 90 51 |
You should never invest in Elicera Therapeutics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Elicera Stock, because this is throwing your money away. Analyzing the key information contained in Elicera Therapeutics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Elicera Therapeutics Key Financial Ratios
Elicera Therapeutics' financial ratios allow both analysts and investors to convert raw data from Elicera Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Elicera Therapeutics over time and compare it to other companies across industries.Elicera Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Elicera Therapeutics's current stock value. Our valuation model uses many indicators to compare Elicera Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Elicera Therapeutics competition to find correlations between indicators driving Elicera Therapeutics's intrinsic value. More Info.Elicera Therapeutics AB is rated # 2 in return on equity category among its peers. It also is rated # 2 in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Elicera Therapeutics' earnings, one of the primary drivers of an investment's value.Elicera Therapeutics Systematic Risk
Elicera Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Elicera Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Elicera Therapeutics correlated with the market. If Beta is less than 0 Elicera Therapeutics generally moves in the opposite direction as compared to the market. If Elicera Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Elicera Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Elicera Therapeutics is generally in the same direction as the market. If Beta > 1 Elicera Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Elicera Therapeutics March 17, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Elicera Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Elicera Therapeutics AB. We use our internally-developed statistical techniques to arrive at the intrinsic value of Elicera Therapeutics AB based on widely used predictive technical indicators. In general, we focus on analyzing Elicera Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Elicera Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 4.71 | |||
| Information Ratio | 0.1568 | |||
| Maximum Drawdown | 28.35 | |||
| Value At Risk | (7.08) | |||
| Potential Upside | 11.54 |
Additional Tools for Elicera Stock Analysis
When running Elicera Therapeutics' price analysis, check to measure Elicera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elicera Therapeutics is operating at the current time. Most of Elicera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Elicera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elicera Therapeutics' price. Additionally, you may evaluate how the addition of Elicera Therapeutics to your portfolios can decrease your overall portfolio volatility.